Abstract: Y-27632 dihydrochloride is a pioneering, small-molecule inhibitor of Rho-associated coiled-coil-containing protein kinases (ROCK1 and ROCK2). In the field of ophthalmology and glaucoma research, Y-27632 has demonstrated significant therapeutic potential, particularly in the management of corneal endothelial diseases such as Fuchs endothelial corneal dystrophy (FECD) and pseudophakic bullous keratopathy (PBK). By competitively inhibiting the ROCK signaling pathway, Y-27632 promotes corneal endothelial cell (CEC) proliferation, migration, and adhesion while suppressing apoptosis and cellular senescence. Furthermore, it has been shown to lower intraocular pressure by relaxing the trabecular meshwork, making it relevant for glaucoma research. Despite its promising pharmacological profile, the clinical translation of Y-27632 is currently limited by its relatively low in vitro potency compared to newer ROCK inhibitors, a short serum half-life, and poor cell membrane permeability. Future research is heavily focused on integrating Y-27632 into cell-based regenerative therapies and developing sustained-release drug delivery systems, such as mucoadhesive films and nanoparticle carriers, to optimize its clinical efficacy and safety in ocular applications.
1. Introduction
The cornea is the transparent outermost layer of the eye, essential for refracting light and maintaining clear vision. Its innermost layer, the corneal endothelium, maintains corneal transparency by actively pumping excess fluid out of the stroma [1]. Diseases that compromise this layer, such as Fuchs endothelial corneal dystrophy (FECD) and pseudophakic bullous keratopathy (PBK), lead to corneal edema and vision loss, traditionally requiring surgical interventions like corneal transplantation [2][4]. Y-27632 dihydrochloride was the first small-molecule inhibitor of Rho-associated coiled-coil-containing protein kinases (ROCK) to be discovered and has since become a cornerstone in researching non-surgical, pharmacological treatments for these conditions [1][6]. By targeting the ROCK pathway, which is implicated in various pathological conditions including glaucoma and endothelial dysfunction, Y-27632 has emerged as a critical compound in ophthalmology for its ability to modulate cell behavior, enhance wound healing, and support cell-based therapies [2][4].
2. Pharmacological Activity
Y-27632 exhibits a broad spectrum of pharmacological activities beneficial for ocular health, primarily centered on tissue regeneration and intraocular pressure (IOP) regulation. In the context of corneal diseases, Y-27632 significantly enhances the proliferation, migration, and adhesion of corneal endothelial cells (CECs) both in vitro and in vivo [1][2][4]. Preclinical models have demonstrated that topical application of Y-27632 accelerates corneal endothelial wound healing, restores normal hexagonal cell morphology, and increases overall cell density [2].
The compound is also highly effective in preventing cell death. For instance, exposing CECs to Y-27632 prior to phacoemulsification (cataract surgery) significantly reduces both early and late apoptosis rates, suggesting a prophylactic role against surgical trauma [3]. In regenerative medicine, Y-27632 is utilized to improve the survival of frozen CECs and enhance the engraftment efficiency of transplanted cells. Clinical studies have shown that injecting cultured human CECs supplemented with Y-27632 into the anterior chamber successfully restores corneal transparency and improves visual acuity in patients with PBK [1][2][4]. Additionally, in glaucoma research, ROCK inhibitors like Y-27632 are known to lower IOP by relaxing the contractility of the trabecular meshwork, thereby enhancing the outflow of aqueous humor [4].
3. Molecular Mechanism of Action
Y-27632 exerts its effects by competitively binding to the catalytic residue of ROCK, thereby inhibiting its kinase activity [5][7]. ROCK1 and ROCK2 are downstream effectors of the small GTPase RhoA. Under normal or pathological activation, the RhoA/ROCK pathway phosphorylates substrates such as myosin light chain (MLC) and LIM kinase, leading to actomyosin-driven cellular contraction, stress-fiber assembly, and reduced cell migration [2][4][6]. By blocking this pathway, Y-27632 reduces cytoskeletal stress and cellular contractility.
In corneal endothelial cells, this reduction in cytoskeletal tension promotes cell cycle re-entry in normally quiescent cells. This is achieved through the upregulation of positive cell cycle regulators like cyclin D1 and the downregulation of inhibitors such as p27Kip1 [2][4]. Furthermore, Y-27632 suppresses apoptosis by inhibiting ROCK/MYOSIN signaling and the P53 pathway, preventing membrane blebbing and nuclear disintegration [4][5]. The compound also mitigates oxidative stress by decreasing the production of reactive oxygen species (ROS) and downregulating inflammatory cytokines, which further supports cell survival and limits fibrotic remodeling (e.g., inhibiting TGF-beta-mediated myofibroblast transformation) [1][3][4].
4. Structure-Activity Relationship (SAR)
Y-27632 is a specific, ATP-competitive inhibitor of both ROCK isoforms (ROCK-1 and ROCK-2) [7]. It acts as a dual inhibitor with a reported inhibition constant (Ki) value of 140 to 220 nM for ROCK-1 and 300 nM for ROCK-2 [2]. Structurally, its physicochemical properties influence its pharmacokinetic behavior. Y-27632 is highly hydrophilic, which results in poor penetration through the lipid bilayer of cell membranes. Consequently, its paracellular transport is limited, and it must be taken up by corneal epithelial cells through carrier-mediated facilitated diffusion in order to reach the deeper corneal endothelial layer [1]. While it was the foundational molecule for ROCK inhibition, its structural profile yields a comparatively lower in vitro potency when contrasted with newer, clinically approved ROCK inhibitors like netarsudil, which boasts a Ki value of 1 nM for both ROCK isoforms [2].
5. Current Limitations
Despite its extensive use in preclinical research, the clinical application of Y-27632 faces several limitations. First, it has not been approved for widespread commercial clinical use as a standalone ophthalmic drug, unlike its successors ripasudil and netarsudil [2]. A major pharmacological drawback is its relatively low potency and short serum half-life, which is estimated to be only 1 to 1.5 hours [2]. Furthermore, its hydrophilic nature restricts its permeability across the ocular surface, limiting the amount of drug that successfully reaches the target tissues in the anterior chamber when administered as conventional eye drops [1][4]. Systemic or high-dose administration of ROCK inhibitors also carries the risk of side effects, with Y-27632 specifically noted for causing symptomatic hypotension due to its vasodilatory effects [1][8]. Finally, there is currently limited pharmacokinetic data available regarding its specific ophthalmic application in humans [2].
6. Future Perspectives
The future of Y-27632 in ophthalmology lies in advanced drug delivery systems and combination therapies. To overcome its poor permeability and short half-life, researchers are developing sustained-release formulations. For example, mucoadhesive hydroxypropyl methylcellulose-polyethylene glycol (HPMC-PEG) films loaded with Y-27632 have been shown to deliver significantly more drug into the cornea over extended periods compared to standard eye drops [4]. Other innovative approaches include coating intraocular lenses with poly(lactic-co-glycolic acid) (PLGA) loaded with Y-27632 to inhibit lens epithelial cell proliferation and prevent posterior capsular opacification after cataract surgery [4].
Additionally, Y-27632 is playing a pivotal role in the evolution of cell-based therapies. Ongoing Phase 1 clinical trials (e.g., NCT05309135) are evaluating the safety and efficacy of intrastromal injections of cultured human corneal endothelial cells combined with varying doses of Y-27632 to treat corneal edema [1][4]. As research progresses, optimizing the dosing regimens, improving targeted delivery modalities, and conducting larger randomized controlled trials will be essential to fully translate the therapeutic potential of Y-27632 into standard clinical practice for corneal diseases and glaucoma [4].
